Moderna to Host R&D Day on Thursday, September 8, 2022
Aug 29th, 2022 7:00 EST
CAMBRIDGE, MA / ACCESSWIRE / August 29, 2022 / Moderna, Inc. (Nasdaq:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced it will host its in-person and virtual R&D Day at 9:00 a.m. ET on Thursday, September 8, 2022.
Moderna's R&D Day will feature presentations from Stéphane Bancel, Chief Executive Officer, Stephen Hoge M.D., President, and Moderna clinical team leaders.
A live webcast will be available under "Events and Presentations" in the Investors section of the Moderna website. A replay of the webcast will be archived on Moderna's website for one year following the presentation.
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna's capabilities have come together to allow the authorized use and approval of one of the earliest and most effective vaccines against the COVID-19 pandemic.
Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years. To learn more, visit www.modernatx.com.
Moderna ContactLavina TalukdarSenior Vice President& Head of Investor Relations617-209-5834Lavina.T[email protected]
SOURCE: Moderna, Inc.